Human Genome Sciences, Inc. (HGSI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Human Genome Sciences, Inc. (HGSI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Paul Lee who wrote (1123)	1/23/2012 4:04:01 PM
From: steve kammerer	of 1127

Is this ready to turn? Last sold at a LOSS is Dec 04 at $11.71. What do you think? http://seekingalpha.com/article/321380-2-high-risk-high-reward-biotechs-that-could-double Human Genome Sciences ( CVG) operates as a biopharmaceutical company. Its principal products in development include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax." (Business Description from Yahoo Finance) 4 reasons HGSI is worth a flyer at $9 a share: Credit Suisse has an "outperform" rating on HGSI as well as a price target of $25 on the stock. Maxim Group just initiated the stock as a "buy" as well. Several insiders bought shares in the $15 to $16 range in August. Although still losing money, HGSI's revenue has gone from under $26mm in FY2006 to a projected $300mm in FY2012. The stock looks like it has bottomed and is gaining technical strength as it has just crossed it 50 day moving average.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next